品名：Seraseq® FFPE MSI-High RM

货号：0710-2236

品牌：SeraCare 

Product Specifications - Seraseq FFPE MSI-High RM 

# of variants：Variable 

Allele Frequency：Variable 

Concentration：N/A 

Fill Size：10 µm 

Total DNA：>200 ng 

Number of vials：1 (tumor only) 

Matrix：FFPE

Details

INTRODUCTION 

Microsatellites are regions of DNA repeats with different lengths, i.e., instability, highlighting DNA mismatch 

repair gene deficiencies. Typical repeat units are between 1-6 base pairs and the number of repeats vary from 

person to person such that each person has a set length of these microsatellites in their genome. 

Measurements of MSI have traditionally been performed using qPCR/CE fragment length analysis methods, 

or immunohistochemistry (IHC), but new methodologies such as digital droplet PCR (ddPCR) and Next 

Generation Sequencing (NGS) are now being applied to determination of MSI status of cancer patients. 

High incidence of microsatellite instability (MSI) has been linked to favorable outcomes in immuno-oncology 

(I-O) treatment response by patients with diseases such as Lynch Syndrome and colorectal cancer. Hence 

determination of MSI status for cancer patients is important in I-O therapeutics management. 

LGC SeraCare has developed microsatellite instability (MSI) reference materials that support qPCR and NGS 

assays that target a range of short tandem repeat regions commonly analyzed for microsatellite instabilities. 

For assays that target specific mono and dinucleotide repeats such as BAT-25, BAT-26, NR-21, NR-24, 

MONO-27, we have created MSI reference materials containing these markers blended at two different allele 

frequency (AF) levels – 5% and 20%. Additionally, for NGS MSI assays that analyze for a large number of 

microsatellite loci across the human genome, we have a human diseased cell line-based MSI-High reference 

material for such analysis. These products are quantitated by PCR (qPCR/CE and ddPCR) and by targeted NGS 

assays to support all product claims. 

FEATURES AND BENEFITS 

• Cell line or plasmid-based MSI reference material mix for analysis in molecular assays or NGS 

• Offered as tumor-only (MSI-High) or tumor-normal (AF5% and AF20%) options 

• Support MSI assay validation, LoD determination, and routine detection of MSI markers in cancer patient 

samples 

• Variant AFs (AF5% and AF20% products) quantitated by ddPCR and qPCR/CE fragment length analysis assays 

• Normal background DNA is a highly characterized GM24385 human genomic DNA known to be microsatellite 

stable (MSS) 

• Manufactured within cGMP compliant and ISO 13485 certified facilities 

维百奥生物代理SeraCare对照及参比物质。

维百奥（北京）生物科技有限公司，自2018年与SeraCare（现隶属于LGC Clinical Diagnostics）合作以来，长期为中国客户

提供包括SeraSeq系列参比物质，领域包括肿瘤、生殖健康和遗传病。SeraCare研发和生产一系列临床参比物质，可以用于任何

研发阶段，以确保临床基因组学检测结果的准确性。

SeraCare参比物质涵盖的范围：

1）Next Generation Sequencing

2）Sanger Sequencing

3）Real-time PCR and digital PCR (dPCR)

4）Microarray

主要特点

1）Ready-to-use reference materials covering clinically-relevant variants and all variant types - SNVs, INDELS, CNVs, 

and RNA fusions

2）Highly multiplexed - provide significantly more data per NGS run, saving sequencing costs

3）Available in multiple formats to suite different workflow needs - purified DNA & RNA, ctDNA, encapsulated ctDNA 

in plasma, and FFPE

4）Manufactured in cGMP-compliant, ISO 13485-certified facilities

5）Stringent product release testing - all variants qualified by dPCR for allele frequencies or copy numbers